Letrozol Stada (Letrozole)

Letrozole blocks the aromatase enzyme, which converts adrenal androgens into estrogen. By inhibiting this conversion, circulating estrogen concentrations drop, depriving estrogen‑dependent breast cancer cells of a key growth signal and limiting tumor proliferation.

The specific dose of Letrozol Stada is determined by the prescribing physician based on the patient’s clinical condition, treatment stage, and individual factors. Healthcare professionals follow approved guidelines and adjust the regimen as needed for safety and efficacy.

Letrozol Stada is contraindicated in pregnancy and breastfeeding because it can interfere with estrogen production essential for fetal development and lactation. Women of child‑bearing potential should use effective contraception and discuss any pregnancy plans with their healthcare provider.

To request Letrozol Stada, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Letrozol Stada (letrozole) is a third‑generation aromatase inhibitor with a high potency and a long half‑life, offering sustained estrogen suppression. Compared with earlier agents such as anastrozole, letrozole often provides slightly greater estrogen reduction, though individual response and tolerability can vary, so choice is guided by clinical judgment.

Letrozol Stada tablets should be stored at ambient temperature below 25 °C, protected from moisture and light. Keep the medication in its original container until use, and avoid exposing it to excessive heat or humidity to maintain potency.

Letrozol Stada is taken orally, usually as a single tablet swallowed with water. The exact timing (e.g., with or without food) follows the prescriber’s instructions, and patients should adhere to the dosing schedule set by their healthcare professional.

Serious risks include severe liver injury, bone fractures due to decreased estrogen, and rare events such as pulmonary embolism. Patients should report signs of jaundice, unexplained bone pain, or sudden shortness of breath to their physician promptly.

Letrozol Stada should not be used by premenopausal women, pregnant or nursing individuals, and patients with known hypersensitivity to letrozole or any tablet excipients. It is also avoided in patients with severe liver impairment unless specifically directed by a specialist.